

Answering Reviewers

Comments from the reviewer were: “Good and valuable paper. It is suitable for publication.”

Editorial Office’s Comments and Suggestions:

As per the Science Editor’s comments, “Core Tip” and “Author Contributions” are included in the revised manuscript. They are also as shown below.

Core Tip

The treatment of clear cell renal cell carcinoma (ccRCC) remains a challenge given its frequent asymptomatic presentation even in metastatic cases and refraction to cytotoxic chemotherapy or radiotherapy. The core of this work reviews the current status of systemic combination drug options in the treatment of metastatic ccRCC. It encompasses the novel and developing combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), with a focus on rationale for use, efficacy, and side effects profiles. It discusses the role of biomarkers in the selection, sequencing and development of future generation of systemic therapeutic options.

Author contributions:

Khetani VV prepared the initial draft of the manuscript; Portal DE and Shah MR contributed in the reviewing and revising of the manuscript; Mayer T and Singer EA revised and edited the manuscript.